AJ-VACCINES
22.4.2020 08:10:11 CEST | Business Wire | Pressemeddelelse
På trods af en igangværende indsats for at udrydde polio, har der været en stigning af registrerede poliotilfælde fra 2018 til 2019. Fremadrettet vil AJ Vaccines ’ antigen reducerende teknologi give mulighed for at udvide udbuddet af poliovaccine, med potentiale for at levere op til 100 millioner doser i femårsperioden 2020-2024, hvilket vil dække den uopfyldte globale efterspørgsel på inaktiverede poliovacciner.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200421005974/da/
En milepælspræstation
Udviklingen af den første dosis reducerede enkelt-komponent inaktiverede poliovaccine er en milepæl for den betydelige investering og innovation, der er foretaget i den danske vaccineproduktion. ”WHO's prækvalifikation er en anerkendelse af vores fortsatte investeringer, som gør det muligt for AJ Vaccines at imødekomme den stigende efterspørgsel på effektive poliovacciner, og vi åbner hermed et nyt kapitel i virksomhedens fortsatte rejse mod at bistå den danske befolkning og et stigende antal mennesker globalt” , siger Mr. Abdulaziz Hamad Aljomaih, hovedinvestor i AJ Vaccines.
En hyldest til dedikerede medarbejdere
Opnåelsen af WHO-prækvalifikationen er en hyldest til medarbejderne for deres engagement og deres bidrag, som har involveret en omfattende gennemgang af produktionsprocesser og kvalitetskontrolprocedurer, uafhængig laboratorietestning, vurdering af filer samt en inspektion af produktionsfaciliteter, der er udført i fællesskab mellem WHO og Lægemiddelstyrelsen i 2019. ”Prækvalifikationen er en anerkendelse af vores engagerede medarbejderes kompetencer og ligger i forlængelse af vores virksomheds vision, der stræber efter en verden fri for alvorlige sygdomme på tværs af generationer” , siger dr. Tabassum Khan, formand for AJ Vaccines.
Betydelige investeringer
Picovax®-udviklingsprojektet er støttet af Bill & Melinda Gates Foundation. ”Siden vores overtagelse af AJ Vaccines i 2017 har vi investeret markant i den strategiske udvidelse af vores produktionsfaciliteter og rekrutteret 200 nye medarbejdere for at sikre AJ Vaccines’ position som en betydelig aktør på vaccinemarkedet, der bidrager til det vigtige strategiske globale mål om at udrydde polio” , siger Jesper Helmuth Larsen, administrerende direktør i AJ Vaccines.
Den nye vaccine vil spille en afgørende rolle for The Global Polio Eradication Initiative (GPEI)
Den nye inaktiverede poliovaccine (IPV) er indikeret til aktiv immunisering mod poliomyelitis ved primær vaccination hos spædbørn fra seks uger og til revaccination af spædbørn, børn og unge. En antigen reduceret IPV giver beskyttelse, der kan sammenlignes med den, der opnås ved andre inaktiverede poliovacciner, der i øjeblikket er tilgængelige. ”Den antigen reducerende teknologi sikrer en tiltrængt forøgelse i udbuddet og vil bidrage til at imødekomme det stigende behov for inaktiveret poliovacciner, der støtter The Global Polio Eradication Initiative” , afslutter Jérôme Cabannes, COO AJ Vaccines.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200421005974/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 21:30:00 CET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 21:15:00 CET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 19:06:00 CET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
SLB Announces Dates for First-Quarter 2026 Results Conference Call26.3.2026 18:00:00 CET | Press release
SLB (NYSE:SLB) will hold a conference call on April 24, 2026, to discuss the results for the first quarter ending March 31, 2026. The conference call is scheduled to begin at 11:00 a.m. US Eastern time and a press release regarding the results will be issued at 7:00 a.m. US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (404) 975-4839 outside of North America approximately 10 minutes prior to the start of the call and the access code is 742955. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/972985185 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until May 1, 2026, and can be accessed by dialing +1 (866) 813-9403 within North America or +1 (929)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum